Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 757-767, December 2006

Immunomodulation in myelodysplastic syndromes

  • Mikkael A. Sekeres, MD, MS (Assistant Professor of Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 216 445 9353; Fax: +1 216 444 9464.
  • Alan List, MD (Professor of Oncology and Medicine, Chief, Malignant Hematology Division, and H. Lee Moffitt Cancer Center & Research Institute Professor of Medicine)

Cleveland Clinic Lerner College of Medicine, Department of Hematologic Malignancies and Blood Disorders, Taussig Cancer Center, Cleveland Clinic Foundation, Desk R35, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA

University of South Florida College of Medicine, 12902 Magnolia Drive, Tampa, FL 33612-9497, USA

The myelodysplastic syndromes (MDS) – bone-marrow stem-cell malignancies that share pathogenetic overlap with acute myeloid leukemia – are characterized by peripheral-blood cytopenias and, in more advanced subtypes, varied degrees of maturation arrest. Premature apoptosis of bone-marrow cellular elements contributes to ineffective hematopoiesis, which is exacerbated by stromal production of inflammatory cytokines. Abrogation of the effects of these cytokines represents an area of active clinical research, particularly in the treatment of low-risk MDS. Agents such as thalidomide, lenalidomide, and infliximab have shown promising efficacy and tolerability in clinical trials, and may represent a springboard for future treatment combinations.

Key words: myelodysplastic syndromes, treatment, outcome, immunomodulation

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6926(06)00038-7

doi:10.1016/j.beha.2006.06.001

Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 757-767, December 2006

Article Tools